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Abstract. Aim: The aim of the study was to evaluate the
incidence of endometriosis-associated ovarian cancer
(EAOC) and compare clinicopathological characteristics and
overall survival (OS) between patients with EAOC and those
with ovarian cancer not associated with endometriosis.
Patients and Methods: We identified EAOC among 203
patients with invasive epithelial ovarian cancer who
underwent complete surgery at our Institution from January
2004 to March 2014. Results: EAOC was present in 45
patients. EAOC was significantly more frequently diagnosed
at an earlier stage of disease (p=0.038). At a median follow-
up time of 32 months, OS among patients with EAOC was
significantly longer (p=0.039). However, stratifying by stage,
the OS advantage of EAOC was not significant. At
multivariate analysis, only stage was an independent
prognostic factor for OS (hazard ratio=5.7; 95% confidence
interval=1.8-18.6; p=0.003). Conclusion: EAOC incidence
was 22.2%. EAOC appears to be diagnosed at an earlier
stage and confers a better OS. However, stratifying by stage,
the advantage in survival of EAOC disappears.
Endometriosis is an oestrogen-dependent benign disease that
shares many features with ovarian cancer, such as the invasive
growth, hormone dependency and recurrence (1).
Epidemiological, histopathological and molecular data suggest
a possible malignant potential of endometriosis. In particular,
oxidative stress and chronic inflammation may play a key role
in neoplastic transformation of endometriosis (1, 2). Atypical
endometriosis is, therefore, considered an intermediate lesion
between endometriosis and ovarian cancer (1). 
The malignant transformation of endometriosis is a rare
event, mostly involving the ovary; however, malignant
transformation of endometriosis has also been observed in
extra-ovarian endometriosis (1, 3, 4).
Many studies report an increased risk of ovarian cancer in
women with endometriosis, especially in those with a long-
standing history of endometriosis (>10 years) and with
endometriosis diagnosed at a young age (<30 years) (5). In
particular, endometriosis-associated ovarian cancer (EAOC)
is predominantly of clear-cell and endometrioid histology and
often diagnosed at a younger age, at an earlier stage, and with
a lower grade, and has a better outcome (2).
In the present study, we evaluated the incidence of EAOC
in a series of cases with invasive epithelial ovarian cancer
treated at our Institution, as well as clinicopathological
characteristics, personal history and outcome, in terms of
overall survival (OS) compared to ovarian cancer not
associated with endometriosis (non-EAOC). 
Patients and Methods
In this retrospective study, by reviewing the medical charts, we
identified EAOC among patients with invasive epithelial ovarian
cancer who underwent complete surgery at the Department of
Gynecology and Obstetrics, Umberto I Hospital, University of Turin,
Italy, from January 2004 to March 2014.
In all cases in which concurrent endometriosis was described in the
final pathological report, a review of the pathological specimen was
carried out by an expert pathologist in Gynaecological Oncology at
the Department of Pathology of the same Hospital in order to confirm
the concurrent presence of endometriosis, the site of occurrence of
endometriosis and to define endometriosis as typical or atypical. We
defined EAOC according to the Van Gorp classification (1), including
all three categories: endometriosis concurrent with ovarian cancer in
the same ovary with histological proof of transition from
endometriosis to cancer (category A), as previously described by
Sampson and Scott (6, 7); ovarian cancer with endometriosis in the
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same ovary but without histological proof of transition (category B);
ovarian cancer with concomitant endometriosis at any other location in
the pelvis (endometriosis in the contralateral ovary), in both ovaries
or extra-gonadal endometriosis (category C). According to the
pathological criteria listed above, we divided all patients with invasive
epithelial ovarian cancer into those with and those with non-EAOC. 
All patients signed a written informed consent allowing that their
blinded clinical data and biological material could be used for
research purposes. 
The patients in both groups were treated according to the same
protocol and operated on the same surgical team specialized in
Gynecological Oncology. Patients with early-stage disease
[International Federation of Gynecology and Obstetrics (FIGO) I-
IIa] underwent complete staging surgery followed by adjuvant
chemotherapy with carboplatin and paclitaxel with the exception of
those with IA and IB grade 1 and 2. Patients with advanced disease
(FIGO IIb-IV) underwent cytoreductive surgery, followed by first-
line chemotherapy with carboplatin and paclitaxel. The patients
unsuitable for upfront cytoreductive surgery received neoadjuvant
chemotherapy with carboplatin and paclitaxel, followed by interval
debulking surgery. Since September 2013 (bevacizumab approval in
Italy), patients with disease from FIGO stage IIIb on received
bevacizumab in addition to standard first-line carboplatin-paclitaxel
chemotherapy, followed by bevacizumab-only maintenance therapy
up to 12 months (8). Residual disease at the end of the main surgical
procedure was defined as: no residual tumour (TR) (optimal
cytoreduction; TR=0) or residual disease ≥1 mm (TR≥1). 
Patients typically underwent clinical follow-up examination
(clinical examination and cancer antigen 125 (CA125) biomarker)
every 3 months in the first two years, every 6 months afterwards
until the fifth year after diagnosis, and every year subsequently.
Abdomino-pelvic computed tomographic scan was prescribed in
cases with symptoms, clinical findings or CA125 elevation etc.
Statistical analysis. Statistical analysis was performed using the
SPSS software for Windows 17 (SPSS Inc., Chicago, IL, USA). The
date of primary treatment was used as the date of diagnosis. OS was
calculated according to the date of death or date lost to follow-up. 
Categorical variables were compared by the Pearson’s chi square
test or by Fisher’s exact test. Numerical variables were compared by
the variance analysis (ANOVA) or with independent-samples t-test.
Normality of the variables distribution was tested by the
Kolmogorov-Smirnov test. Survival curves were estimated using the
Kaplan–Meier method and compared by the log-rank test. Cox
proportional hazards regression was used for multivariate analysis.
Variables included in the multivariate analysis were those found to be
statistically significant in the univariate analyses. Hazards ratios
(HR) and 95% confidence intervals (95% CI) were used to calculate
the relative risk of death or relapse for each variable of interest while
adjusting for other covariates. 
All p-values are two-tailed and a p-value of less than 0.05 was
considered statistically significant.
Results
Patients. In the study period, we identified 203 patients
treated with complete surgery at our Institution for invasive
epithelial ovarian cancer. According to the pathological
criteria described above, we identified 45 (22.2%) patients
with EAOC and 158 with non-EAOC (77.8%). 
In two cases of EAOC, atypical endometriosis was found:
in one case it was located in the same ovary affected by
cancer with histological proof of transition from
endometriosis to cancer; in the second case, concurrent
endometriosis was found in the bowel wall. In the other 43
cases of EAOC, concurrent endometriosis was typical. 
According to the Van Gorp classification (1), concurrent
endometriosis was found in the same ovary affected by
cancer in eight patients, among them, one category A; in the
other seven, only typical endometriosis was present (category
B). In two patients, endometriosis was found in the
contralateral ovary, and in one patient, endometriosis was
present in both ovaries; in the remaining 34 women
concurrent endometriosis was present outside the ovaries
(category C) (Table I).
Comparison of clinicopathological characteristics between
EAOC and non-EAOC. The clinicopathological data were
compared between the two groups as shown in Table II. 
Mean age at diagnosis was similar for the two groups and
as was the number of pregnancies. In the EAOC group, only
six women (13.3%) reported a personal history of
endometriosis. Around half of the non-EAOC tumours were
serous, compared to 37.8% in the EAOC group (p=0.13).
Among EAOCs, around one-third were endometrioid and
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Table I. Classification of endometriosis-ssociated ovarian cancer (EAOC) according to Van Gorp categories in this study.
Van Gorp category Definition of EAOC Patients with EAOC (n=45)
A Endometriosis in the same ovary affected by cancer with histological proof of 1 (2.2%)
transition from endometriosis to cancer 
B Endometriosis in the same ovary affected by cancer without histological proof of 7 (15.6%)
transition from endometriosis to cancer
C Endometriosis in the contralateral ovary 2 37 (82.2%)
Endometriosis in both ovaries 1
Extragonadal endometriosis (uterus, fallopian tube, parametrium, bowel, peritoneum, 34
omentum, appendix, utero-sacral ligaments) 
11.1% were clear cell (versus 22.8% and the 6.3% among non-
EAOCs, respectively). EAOC tumours were significantly more
frequently diagnosed at an earlier stage of disease compared to
non-EAOC (p=0.038). According to Kurman and Shih
categories (9), type I ovarian cancer was more frequent in the
EAOC group (51.1% versus 40.5%, respectively); on the
contrary, type II ovarian cancer was more represented in the
non-EAOC group (59.5% versus 48.9% of the EAOC group).
However, these differences were not significant (p=0.205).
Stratifying the whole series by stage, 50 patients had early-
stage disease (FIGO stage I-IIA; 24.6%) and 153 advanced-
stage (FIGO stage IIB-IV; 75.4%). 
Among the 50 patients with early-stage disease, 15 had
EAOC. Comparing EAOC to non-EAOC, the mean age at
diagnosis was 57 years for both groups. We found a non-
significant difference in the histotype distribution in those with
early-stage disease: in the EAOC group, we found fewer serous,
no undifferentiated and more clear-cell and mucinous tumours;
the most frequent histotype in both groups was endometrioid.
Among those with advanced disease, 83 patients (54.2%)
underwent primary debulking surgery and 70 (45.8%)
received neoadjuvant chemotherapy followed by interval
debulking surgery. Comparing the 30 patients with EAOC
(19.6%) with the 123 with non-EAOC (80.4%), no significant
differences regarding age at diagnosis and the number of
pregnancies were found. In both groups, mucinous and clear-
cell tumours were under-represented and the main histotype
was serous. Among EAOCs, 20% were endometrioid
Bounous et al: Endometriosis-associated Ovarian Cancer
3447
Figure 1. Overall survival (OS) of patients with ovarian cancer according
to the presence (1) or absence (2) of associated endometriosis.
Table II. Clinicopathological characteristics of patients with invasive epithelial ovarian cancer compared according to the concurrent presence
(EAOC) or absence of endometriosis (non-EAOC).
EAOC Non-EAOC p-Value
(n=45) (n=158)
Mean (± SD) age at diagnosis, years 59 (±9.6) 60.4 (±11) 0.47
Number of pregnancies None 12 (26.7%) 54 (34.2%) 0.343
≥1 33 (73.3%) 104 (65.8%)
Histotype Serous 17 (37.8%) 82 (51.9%) 0.13
Endometrioid 13 (28.9%) 36 (22.8%) 0.461
Clear cell 5 (11.1%) 10 (6.3%) 0.29
Mucinous 4 (8.9%) 9 (5.7%) 0.461
Undifferentiated 6 (13.3%) 21 (13.3%) 0.461
Grading G1 2 (4.4%) 10 (6.3%) 0.313
G2 8 (17.8%) 14 (8.9%) 0.313
G3 33 (73.3%) 130 (82.3%) 0.260
Gx 2 (4.4%) 4 (2.5%) 0.313
Kurman and Shih category (9) Type I (low-grade serous, endometrioid, mucinous, clear cell) 23 (51.1%) 64 (40.5%) 0.205
Type II (high-grade serous and undifferentiated) 22 (48.9%) 94 (59.5%)
FIGO stage I 13 (28.9%) 34 (21.5%) 0.734
II 3 (6.7%) 9 (5.7%)
III 25 (55.6%) 97 (61.4%)
IV 4 (8.9%) 18 (11.4%)
Early-stage disease FIGO stage I-IIa 15 (33.3%) 35 (22.2%) 0.038
Advanced-stage disease FIGO stage IIb-Iv 30 (66.7%) 123 (77.8%)
Surgery Upfront surgery 28 (62.2%) 105 (66.5%) 0.598
Interval debulking surgery 17 (37.8%) 53 (33.5%)
Residual disease 0 37 (82.2%) 109 (69%) 0.090
≥1 mm 8 (17.8%) 49 (31%) 0.081
(compared to 15.4% in the non-EAOC group) and 20% were
undifferentiated (versus 13% in the non-EAOC group)
(p>0.05). Around 90% of tumours in both groups were high
grade. No significant difference in terms of cytoreduction
were seen between the two groups.
Comparison of prognosis between EAOC and non-EAOC. At
a median follow-up of 32 months (range=3-107 months), OS
among those with EAOC was significantly longer (p=0.039),
as shown in Figure 1. The median survival among non-EAOC
patients was 88 months (95% CI=57.7-118.2 months), while
among those with EAOC, it had not been reached
(mean=91.9 months, 95% CI=80.2-103.7 months). 
The difference in OS did not hold when stratification by
stage was performed. Furthermore, we compared the OS
according to the presence of ovarian-associated endometriosis
(N=9), the presence of extra-ovarian-associated endometriosis
(N=36), and the absence of concurrent endometriosis
(N=158). In the follow-up period, 0, 4 and 6 deaths due to
disease, respectively, were observed for these three groups.
However, possibly due to the small number of events, these
differences were not significant (p=0.103). 
In order to identify the independent prognostic factors for
OS, we performed univariate and multivariate analyses. At
univariate analysis, advanced stage, residual disease ≥1 mm,
the concurrent presence of endometriosis and high tumour
grade were significant negative predictors for poorer OS. At
multivariate analysis, only higher stage remained as an
independent prognostic factor for poorer OS (HR=5.7; 95%
CI=1.8-18.6; p=0.003).
Discussion
Endometriosis is associated with an increased risk of ovarian
cancer (relative risk=1.4-8.95) and the prevalence of
endometriosis in ovarian cancer ranges between 3.4 and 52.6%
in the literature (5). This wide variability is due to the different
definitions of EAOC adopted by authors. EAOC can be strictly
defined as the presence of ovarian endometriosis in the same
ovary affected by cancer with histological proof of transition
from endometriosis to cancer [category A according to Van
Gorp classification (1), as considered by Sainz de la Cuesta et
al. (10), Ogawa et al. (11), Valenzuela et al. (12), Kumar et al.
(13), or according to the less stringent criteria as endometriosis
in the same ovary affected by cancer without histological proof
of transition from endometriosis to cancer (category B) or even
as concurrent extra-gonadal endometriosis (category C). 
In our series, the proportion of EAOCs was 22.2%. Most
tumors with concurrent endometriosis (82%) were in category
C according to Van Gorp classification (1); 15% were in
category B and only one patient was in category A. The same
definition of EAOC adopted in our study has been used by
others (3, 14, 15). The Sampson and Scott criteria to define
category A (1, 6, 7) are difficult to meet for different reasons.
Sampling techniques cannot be extensive enough to detect all
foci of endometriosis adjacent to tumours, especially, if the
study is retrospective and sampling was performed with the
main goal of studying tumour characteristics and not for
identifying concurrent endometriosis. Furthermore, the tumour
can be so aggressive that the endometriosic tissue has been
destroyed or only a minor residual component, difficult or
even impossible to detect, is left. 
Many studies have been performed in order to understand
whether EAOC is a clinically distinct entity. According to the
currently accepted dualistic model of Kurman and Shih for
the pathogenesis of epithelial ovarian cancer (9), type I
tumours include endometrioid, clear-cell, mucinous and low-
grade serous carcinoma, and usually have an indolent clinical
behaviour, are often detected in early stage, rarely harbour
p53 gene mutations, are genetically stable, carry mutation of
Kirsten rat sarcoma virus (KRAS), phosphatase and tensin
homolog (PTEN), AT-rich interactive domain 1A (ARID1A)
genes (1, 2), and pre-malignant lesion such as borderline
tumors and endometriosis can be identified. Type II tumours
include high-grade serous and undifferentiated carcinoma,
have a very aggressive clinical behaviour, are usually
advanced stage at presentation, often harbour p53 gene
mutations, and are genetically unstable.
EAOCs frequently exhibit the favourable features of type
I tumours, often being diagnosed at an earlier stage and at a
younger age, and are associated with nulliparity and
infertility (2).
Wang et al. found that concurrent endometriosis was
significantly more frequent among those with type I tumours
(14). In our series, the same trend was observed: type I tumors
were more frequent among those with EAOC; on the contrary,
type II tumors were more frequent in the non-EAOC group.
However, the difference was not statistically significant.
In our series, EAOCs were significantly more frequently
diagnosed at an early stage, consistent with previous findings
(2, 13, 16, 17). The earlier diagnosis of EAOC may be due
to the symptoms associated with endometriosis (pelvic pain
or adnexal mass) or to the concurrent presence of endometrial
lesions (polyps, hyperplasia and endometrial carcinoma) (1). 
In our study, early-stage EAOCs were 46.7% endometrioid,
26.7% clear-cell, 20% mucinous, 6.7% serous and none was of
undifferentiated histotype. The high prevalence among early-
stage EAOCs of endometrioid and clear-cell tumours, the
absence of undifferentiated tumours and the small number of
serous tumours is consistent with the literature (2-4). 
In the literature, a younger age at diagnosis is reported for
those with EAOC (2, 14, 17-20). In our series, we found no
differences in the mean age at diagnosis between those with
EAOC and those with non-EAOC.
In our study, only 13.3% of patients with EAOC reported a
personal history of endometriosis. Most women did not know
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they had endometriosis, as also reported in other studies (14).
If these data are confirmed, many doubts will be raised as to
the feasibility of preventing EAOC with a strict follow-up of
women with endometriosis.
We would have expected a higher proportion of nulliparous
women among those with EAOC (2, 20) due to the close
relationship between endometriosis and infertility; in our
series, no significant difference was observed between the
two groups as to parity. 
As described in the meta-analysis by Kim et al. (2), we
also found no significant difference in optimal cytoreduction
between the two groups. 
In patients with EAOCs, a significantly longer OS was
recorded, both in our and in other studies (2, 13, 16). Other
authors, instead, saw no benefit in OS, but only a longer
disease-free interval (17, 19). Stratifying our series by stage,
no significant difference was observed in OS between those
with EAOC and those with non-EAOC. Similar findings were
reported by others who evaluated the OS of patients with
EAOC according to FIGO stage (13, 17, 20). At multivariate
analysis, only higher stage of disease was a significant
independent predictor of poorer OS (HR=5.7; 95% CI=1.8-
18.6; p=0.003). 
In conclusion, the association of endometriosis with
ovarian cancer is relevant. The advantage in survival
associated with EAOC seems more related to its favourable
features, disappearing after stratifying by stage, thus
suggesting a role of endometriosis as a precursor of cancer
and not as a promoter of cancer after its onset (2). 
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